Industry Briefing
A single destination for timely, editor-curated robotics news from around the world.
Harriet having it all
Harriet Latham Robinson, a distinguished molecular biologist and alumna of Boston University, has made significant contributions to her field while also nurturing personal relationships and pursuing adventurous experiences. Throughout her career, which spans several decades, Robinson has engaged in groundbreaking research that has influenced the understanding of molecular biology, earning her recognition both in the United States and internationally, including in Moscow. Her journey reflects a unique blend of professional dedication and a commitment to maintaining a rich personal life, showcasing how one can thrive in a demanding scientific career while also valuing family and friendships. Robinson's story serves as an inspiration to many in the scientific community, illustrating the balance between work and personal fulfillment.
Profile Alumni/ae Biology Cancer Vaccines History of science
New HySIL lens design makes high-resolution 3D brain and cancer imaging widely accessible
A team from Columbia University has unveiled a groundbreaking microscopy technology that promises to significantly enhance three-dimensional imaging capabilities. This innovative approach, announced in October 2023, aims to improve the visualization of biological structures at unprecedented resolutions. The development is driven by the need for more detailed imaging techniques in various scientific fields, including biology and materials science. By utilizing advanced optical methods, the researchers have created a system that allows for clearer and more accurate representations of complex samples. This advancement could lead to major breakthroughs in understanding cellular processes and developing new materials, ultimately transforming research methodologies across multiple disciplines.
Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has been highlighted as a promising penny stock following a recent endorsement from research firm Citizens, which reaffirmed a Market Outperform rating and set a price target of $5. This assessment comes after a compelling presentation at the American Society of Clinical Oncology (ASCO) conference on June 1, where the company showcased the efficacy, safety, and workflow data of its candidate drug, Amtagvi, for treating advanced melanoma. Citizens emphasized the importance of timely referrals to adoptive T-cell therapy centers to improve patient outcomes. Under the leadership of CEO Frederick Vogt, Iovance is actively pursuing commercial expansion and adoption of Amtagvi, responding to a surge in market demand. The company is also making strides in treating non-small cell lung cancer, sarcoma, and first-line melanoma, positioning itself for long-term revenue growth through ongoing and new clinical trials. Iovance specializes in tumor-infiltrating lymphocyte (TIL) therapies, which involve harvesting and multiplying a patient’s immune cells to create personalized treatments aimed at targeting solid tumors. While IOVA shows potential as an investment, analysts suggest that some AI stocks may offer greater upside with less risk.
The forgotten organ that could predict how long you live
Researchers at Mass General Brigham have uncovered significant insights into the role of the thymus, a small organ crucial to the immune system, in promoting healthy aging and improving cancer survival rates. Utilizing artificial intelligence to analyze CT scans from tens of thousands of adults, the study revealed that individuals with healthier thymuses experienced longer lifespans and notably reduced risks of heart disease, cancer, and overall mortality. This research, which sheds light on the previously underestimated importance of the thymus beyond childhood, highlights the potential for new approaches in understanding aging and disease prevention. The findings suggest that maintaining thymus health could be a key factor in enhancing longevity and reducing the incidence of serious health conditions.
Four from MIT named 2026 Searle Scholars
Computational neuroscientist Sven Dorkenwald and cell biologist Whitney Henry, alongside two alumni from the Massachusetts Institute of Technology (MIT), have been honored for their outstanding contributions to early-career research. This recognition highlights their innovative work in their respective fields, showcasing the impact of their research on advancing scientific understanding. The awards were announced recently, celebrating the achievements of these emerging scholars and their potential to shape future developments in neuroscience and cell biology. Their recognition serves to inspire other young researchers and underscores the importance of fostering talent in the scientific community.
Awards, honors and fellowships Faculty Alumni/ae Research Neuroscience Biology
Single-molecule tracker illuminates workings of cancer-related proteins
A team of researchers has developed advanced microscopy and nanotechnology techniques to monitor the activity of individual proteins in real-time. This innovative approach allows scientists to gain unprecedented insights into protein dynamics, which are crucial for understanding various biological processes and diseases. The research, conducted in a state-of-the-art laboratory, aims to enhance the understanding of cellular mechanisms and potentially lead to breakthroughs in medical treatments. By tagging proteins with custom-built nanotechnology, the team can visualize and track their movements and interactions, providing valuable data that could inform future studies in biochemistry and molecular biology. This work represents a significant advancement in the field, promising to deepen our comprehension of life at the molecular level.
Research Proteins Cells Chemistry Imaging Cancer
How Melbourne’s AI and Data Center Flywheel Is Accelerating Research Innovation
Melbourne is solidifying its status as a global hub for artificial intelligence (AI) research and advanced engineering, driven by significant investments in infrastructure and a growing concentration of talent. The city, renowned for hosting major events like the Australian Open and Formula 1 Grand Prix, is now leveraging its organizational capabilities to support large-scale compute and data-intensive research. In February 2026, Monash University unveiled MAVERIC, Australia's largest university-based AI supercomputer, developed in collaboration with NVIDIA and Dell Technologies. This state-of-the-art facility is designed to enhance medical research, enabling Australian scientists to work with sensitive datasets securely. The supercomputer exemplifies Melbourne's commitment to fostering cross-disciplinary collaborations and advancing research in fields such as cancer detection and drug discovery. Melbourne's infrastructure is further bolstered by the expansion of data centers, including CDC Data Centres' new campus, which will provide over 800 megawatts of digital capacity essential for AI workloads. The city's strategic investments, including a AUD $2 billion AI infrastructure hub in Fishermans Bend, are positioning it as a national leader in high-performance AI. Moreover, Melbourne's selection to host international technology conferences, such as Data Center World Australia and The AI Summit Australia in September 2026, underscores its growing influence in the global AI landscape. These events facilitate knowledge transfer and collaboration among researchers, reinforcing Melbourne's role as a key player in the future of AI and data-driven research.
Australia Artificial-intelligence Research-centers Applied-ai Conferences
Do We Really Need Smarter AI to Cure Cancer?
Major tech companies like Meta and OpenAI are heavily investing in the development of artificial general intelligence (AGI) and artificial superintelligence (ASI), with estimates suggesting over a trillion dollars has already been allocated to artificial intelligence (AI) initiatives. Despite the excitement surrounding these advancements, Emilia Javorsky, director of the Futures program at the Future of Life Institute, cautions against over-reliance on future AI capabilities to solve complex health issues like cancer. In her March essay, "AI vs Cancer," Javorsky critiques the notion that AGI or ASI could cure cancer, emphasizing that cancer is not a singular disease but a collection of highly individualized conditions requiring tailored treatments. Javorsky argues that while current AI applications are making strides in areas such as drug discovery and clinical trials, the focus should shift towards collecting comprehensive health data and improving existing medical tools rather than solely investing in advanced AI technologies. She advocates for a balanced approach that prioritizes effective resource allocation in cancer research and treatment. Javorsky's insights highlight the importance of leveraging existing AI capabilities to enhance patient care and accelerate medical innovation, while also addressing systemic challenges within the healthcare system. Her perspective offers a hopeful outlook on the potential for AI to contribute meaningfully to cancer management and treatment.
Medical-ai Cancer Oncology Agi Superintelligence Cancer-treatments
SquareMind raises $18M for robotic dermatology platform
Squaremind has successfully secured $18 million in funding to develop Swan, an innovative robotic platform designed to automate full-body skin imaging aimed at early cancer detection. This significant investment will enable the company to enhance its technology, which is poised to improve diagnostic accuracy and efficiency in dermatology. The funding round reflects a growing interest in advanced medical technologies that leverage robotics and artificial intelligence to address critical healthcare challenges. By streamlining the imaging process, Swan aims to facilitate timely interventions for skin cancer, ultimately contributing to better patient outcomes.
Artificial Intelligence Cobot Arms Healthcare Robotics News Squaremind
AI identifies early risk patterns for skin cancer
A comprehensive study conducted in Sweden has demonstrated that artificial intelligence can effectively identify individuals at an elevated risk of melanoma by analyzing routine health data. The research revealed that advanced AI models significantly surpassed traditional methods in accuracy, successfully pinpointing high-risk groups. Notably, some individuals identified by the AI system were found to have as much as a 33% likelihood of developing melanoma within a five-year period. This innovative approach holds the potential to revolutionize melanoma screening by enabling more precise and targeted interventions for at-risk populations.
AI maps the hidden forces shaping cancer survival worldwide
A team of researchers has harnessed artificial intelligence to gain insights into the stark disparities in cancer survival rates globally. By examining cancer data and health system information from 185 countries, the AI model identifies key factors influencing survival outcomes. Notably, it highlights the importance of access to radiotherapy, the presence of universal health coverage, and the economic strength of nations as critical elements associated with improved survival rates. This innovative approach aims to enhance understanding of the underlying reasons for these differences, potentially guiding future health policies and interventions to improve cancer care worldwide.
Stanford’s AI spots hidden disease warnings that show up while you sleep
Researchers at Stanford University have created an innovative artificial intelligence system capable of predicting future disease risks based on data collected from a single night of sleep. This advanced technology analyzes intricate physiological signals, identifying hidden patterns in brain activity, heart function, and breathing. The AI has demonstrated success in forecasting potential risks for serious health conditions, including cancer, dementia, and heart disease. The findings indicate that sleep may hold crucial early health warnings that have been largely ignored by the medical community.
A new tool is revealing the invisible networks inside cancer
Spanish researchers have developed a groundbreaking open-source tool named RNACOREX, designed to uncover the complex genetic networks that drive cancer. This innovative software can analyze thousands of molecular interactions simultaneously, providing insights into how genes communicate within tumors and their implications for patient survival. RNACOREX has been rigorously tested across 13 different cancer types, utilizing international data to validate its effectiveness. Remarkably, the tool matches the predictive capabilities of advanced AI systems while offering clear and interpretable explanations, a feature that is often lacking in contemporary analytics. This advancement aims to enhance scientists' understanding of tumor behavior, potentially leading to improved cancer treatment strategies.
AI detects cancer but it’s also reading who you are
Recent research has revealed that artificial intelligence tools developed for diagnosing cancer from tissue samples are capable of inferring patient demographics from pathology slides, which can result in biased outcomes for specific groups. This bias is attributed to the training methods and the data exposure of these AI models, rather than solely the absence of certain samples. The findings highlight a critical issue in the development of AI diagnostic tools, emphasizing the need for more inclusive data sets to ensure equitable healthcare outcomes. Furthermore, researchers have proposed effective strategies to significantly mitigate these disparities, suggesting that improvements in AI training processes could enhance diagnostic accuracy across diverse patient populations.
